UPDATE: Forma takes aim at Agios with new AML complete remission data
Forma Therapeutics went public this year and raised $320 million in large part on the strength of their Phase I/II sickle cell program. But their non-core programs also held promise, including that they could go toe-to-toe with Agios on acute myeloid leukemia. Today, the Massachusetts biotech announced they’ve done that — almost to a tee.
On Tuesday, Forma announced that, in a pivotal Phase II study, its AML drug olutasidenib led to a complete remission in 30% of relapsed or refractory IDH1m-positive patients. Combine that with a 3% rate of complete remission with partial hematologic recovery, and you get a 33% CR/CR+ rate — virtually identical with the 32.7% CR/CR+ rate that Agios’ Tibsovo showed in a pivotal study on these patients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.